Aparna Balasubramanian, MD, assistant professor of medicine, Johns Hopkins School of Medicine, and attendee of the CHEST Annual Meeting 2023, talks about the necessity of challenging measurements like race-specific equations that can create harmful assumptions.
Aparna Balasubramanian, MD, assistant professor of medicine, division of pulmonary and critical care, Johns Hopkins School of Medicine, discusses the need to contest previously held beliefs, such as the use of race-specific equations that can help detect chronic obstructive pulmonary disease (COPD). Balasubramanian is attending the CHEST Annual Meeting 2023, where themes of equity are woven throughout the agenda.
Transcript
Some of your studies focus on how disparities impact pulmonary care. One study called "Early Evidence of COPD Obscured by Race-Specific Prediction Equations" found that race-specific equations underestimate disease severity amongst African-Americans, with these effects especially evident in early disease and might result in late COPD detection.
What are some ways race-specific equations can be rectified, and how can they be implemented into clinical practice?
Race-specific equations are a result of observed epidemiologic data that suggest that average lung function is lower among Blacks than in Whites. So generally, the race-specific equations were meant to account for that. But that has led to an assumption that that lower lung function is expected or normal among Black individuals. This study specifically was trying to demonstrate that by using these equations and buying into that assumption, we underestimate disease severity and underdiagnose disease in specifically COPD. The field was really working very hard at trying to identify reasonable alternatives to address this issue, because obviously, we don't want to be propagating a method for interpretation of lung function that is harmful to one specific community, one specific population.
Current recommendations are to use a single reference equation, which is known as GLI Global, or the [Global Lung Function Initiative] global equation, for all races to try and mitigate the kind of selective underestimation that we just described. The benefit of that equation is that it treats low lung function values similarly across all races. Of course, that does sort of fall into a bin of a one-size-fits all. There's a lot of research surrounding alternatives that might be a little bit better that are a bit more conscientious of differences across populations.
I think, generally, the community is trying to think about non–reference equation–based methods for understanding lung function, things like using just FEV1 [forced expiratory volume in 1 second] in its absolute form, using something like FEV1Q [FEV1 quotient] or FEV1 over height squared, but there's a lot more work that has to be done in that arena. I think the other piece of this, in terms of rectifying the issues surrounding race-specific equations, is understanding how we apply race-specific equations and whether or not absolute thresholds or cutoffs make sense for qualifying for therapies or employment or disability.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More